Areas of Focus
- Pathogenesis and treatment of brain glioma
- Mechanisms and gene therapy of rare neuromuscular diseases
Publications
- Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas, Wang Y, Wild AT, Turcan S, Wu W, Sigel C, Klimtra D, Ma X, Gong Y, Holland EC, Huse JT, Chan TA, 2020
- G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma, Wang Y, Yang J, Wild AT, Wu W, Shah R, Danussi C, Riggins GJ, Kannan K, Sulman EP, Chan TA, and Huse JT, 2019
- Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence, Turcan S, Makarov V, Taranda J, Wang Y, Fabius AWM, Wu W, Zheng Y, 2018
- Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling, Danussi C, Bose P, Parthasarathy PT, Silberman PC, Arnam JSV, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang P, Creighton CJ, Deneen B, Miller CY, Picketts DJ, Huse JT, 2018
- Activation of protein synthesis in mouse uterine epithelial cells by estradiol-17β is mediated by a PKC–ERK1/2–mTOR signaling pathway, Wang Y, Zhu L, Kuokkanen S, and Pollard JW, 2015
- GSK-3β mediates in the progesterone inhibition of estrogen induced cyclin D2 nuclear localization and cell proliferation in cyclin D1−/− mouse uterine epithelium, Wang Y, Feng H, Bi C, Zhu L, Pollard JW, Chen B, 2007
Awards
- Pujiang Talent Plan (2020)